Showing results (51-60 of 74) with videos related to
Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II studyO Glehen, F Mithieux, D Osinsky, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2002
Oral vinorelbine: feasibility and safety profileA Depierre, G Freyer, J Jassem, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 2005
Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO studyG Freyer, J-F Geay, S Touzet, et al.British Journal of Cancer|August 17, 2000
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groupsG Freyer, P Rougier, R Bugat, et al.Annals of Neurology|June 1, 1997
Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13?K Wilhelmsen, D Mirel, K Marder, et al.British Journal of Cancer|July 14, 2012
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumoursG Freyer, N Isambert, B You, et al.British Journal of Clinical Pharmacology|September 30, 2000
Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre studyG Freyer, B Tranchand, B Ligneau, et al.Annals of Surgical Oncology|October 7, 2003
Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive proceduresO Glehen, D Osinsky, E Cotte, et al.CPT: Pharmacometrics & Systems Pharmacology|February 24, 2016
Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settingsS Wilson, M Tod, A Ouerdani, et al.Clinical Pharmacology and Therapeutics|December 17, 2008
A dynamic model of hand-and-foot syndrome in patients receiving capecitabineE Hénin, B You, E VanCutsem, et al.Pageof 8